Cancer Treatment Today

V erzenio was initially s FDA approved in combination with fulvestrant to treat women with hormone receptor (HR)positive, human epidermal growth factor receptor 2 (HER2)negative advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), whose disease has progressed after hormonal therapy alone to treat adults with HRpositive, HER2negative advanced breast cancer or metastatic breast cancer whose disease has progressed after hormonal therapy and prior chemotherapy.FDA also approved Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced or metastatic breast cancer.

he MonarchE trial showed an increasing benefit for adding abemaciclib to endocrine therapy in the adjuvant treatment of early high-risk hormone receptor–positive, HER2-negative breast cancer, regardless of Ki67 index.

Johnston S, O’Shaughnessy J, Martin M, Huober J, Toi M, Sohn J, André VAM, Martin HR, Hardebeck MC, Goetz MP. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. NPJ Breast Cancer. 2021 Jun 22;7(1):80.
O’Shaughnessy J, Rastogi P, Harbeck N, et al: Adjuvant abemaciclib combined with endocrine therapy: Updated results from monarchE. ESMO Virtual Plenary Session. Presented October 14, 2021.

2. Harbeck N, Rastogi P, Martin M, et al: Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Updated efficacy and Ki67 analysis from the monarchE study. Ann Oncol. September 29, 2021 (early release online).

3. O’Shaughnessy JA, Johnson S, Harbeck N, et al: Primary outcome analysis of invasive disease-free survival for monarchE. 2020 San Antonio Breast Cancer Symposium. Abstract GS1-01. Presented December 9, 2020.